Loading
An ADC kills tumour cells in a way that alerts the immune system; a checkpoint inhibitor lets the immune system finish the job.
Proven in urothelial cancer (EV-302: enfortumab vedotin + pembrolizumab, OS HR 0.47) and TNBC (ASCENT-04: sacituzumab govitecan + pembrolizumab, PFS HR 0.65, approved 2026). TROPION-Breast05 (Dato-DXd + durvalumab) and multiple lung trials follow. Overlapping pneumonitis risk with DXd ADCs needs care.
Shares EV-302 / KEYNOTE-A39, Enfortumab vedotin, Bladder & urothelial cancer, Antibody-drug conjugate (ADC).
Shares EV-302 / KEYNOTE-A39, Enfortumab vedotin, Bladder & urothelial cancer, Pembrolizumab.
Shares Enfortumab vedotin, Bladder & urothelial cancer, Antibody-drug conjugate (ADC), Pembrolizumab.
Shares Enfortumab vedotin, Bladder & urothelial cancer, Antibody-drug conjugate (ADC), Pembrolizumab.
Shares An oncology patent pool for combination trials across companies, cGAS-STING innate sensing, Pembrolizumab, Immune checkpoint inhibitors.
Shares Enfortumab vedotin, Bladder & urothelial cancer, Antibody-drug conjugate (ADC), Pembrolizumab.
Shares Enfortumab vedotin, Bladder & urothelial cancer, Antibody-drug conjugate (ADC), Pembrolizumab.
Shares EV-302 / KEYNOTE-A39, Enfortumab vedotin, Bladder & urothelial cancer, Pembrolizumab.